CA1223598A

CA1223598A - DOPAMINE-.beta.-HYDROXYLASE INHIBITORS

Info

Publication number: CA1223598A
Application number: CA000451719A
Authority: CA
Inventors: James S. Frazee; Carl Kaiser; Lawrence I. Kruse
Original assignee: Smith Kline and French Canada Ltd
Current assignee: GlaxoSmithKline Inc
Priority date: 1983-04-12
Filing date: 1984-04-11
Publication date: 1987-06-30
Also published as: AU2672284A; JPS59199678A; DK99791A; DE3475905D1; GR79885B; AU575558B2; US4532331A; DK190284D0; ES539565A0; ES8602686A1; DK162629C; PT78389B; DK99791D0; ATE39686T1; DK99691D0; IE840875L; GR79907B; IE57234B1; ES8601909A1; DK162629B

Abstract

Title Dopamine .beta.-hydroxylase Inhibitors Abstract of the Disclosure Potent DBH Inhibitors having the formula:

Description

TITLE
Dopamine-~-hydroxylase Inhibitors FIELD OF THE INVENTION
This invention relates to inhibitors of dopamine-~-hydroxylase.

In the catecholamine biosynthetic pathway, Tarzan is converted in three steps to norepinephrine (NE). Intermediates are dihydroxyphenylalanine (DOPE) and dopamine (DA). The latter is hydroxylated to no repine-shrine by dopamine-~-hydroxylase (DBH) in the presence of oxygen and ascorbic acid.
Inhibition of catecholamine activity has been found to decrease hypertension. See, for example, Malta et at., Olin. Harm. Thor. 14, 541 (1973), and Tories et at., Japan Circa J. 35, 339 (1971). Weinshilboum, Olin. Pro. 55, 39 (1980), reviews compounds which inhibit catecholamine activity by interfering with adrenergic receptors. Alternatively, the catecholamine biosynthetic pathway can be suppressed at any of the three steps, resulting in decreased levels of NE. In addition to decreasing hypertension, inhibitors of NE synthesis are active as diuretics, natriuretics, cardiotonics and vasodilators. Inhibition of DBH activity can have the added advantage of increasing levels of DA, which as reported by Earache et at., "New Anti hypertensive Drugs,"
Spectrum Publishing, 1976, pp. 409-432, has been found to AL

1 have selective vasodilator activity at certain concentrations.
DBH inhibitors have also been shown to reduce or prevent formation of gastric ulcers in rats by Haddock et at., "Catecholamine and Strauss edit. by Us din et at, Permagon Press, Oxford, 1976, pp. 159-165 and by Osumi et alp, Japan. J. Pharmacol~ 23, 904 (1973)~
Although there are many known inhibitors of DBH, none of these agents has found clinical application 10 because of non-specific, often toxic, properties they possess. Fusaric acid, for example, ha been found to be hepatotoxic. See, for example, Tories et at., Japan.
Cur. J. 35, 339 (1971) and references cited therein.
Presumably, the picolinic acid structure interacts with a 15 number of metalloproteins and enzymes in non-specific fashion to produce observed side effects.
In U. K. specification 1,155,580 are disclosed compounds having the formula:

.
SO

Al No wherein R2 and R3 can be H and Al can be substituted phenol. The compounds are said to have analgesic, anti-inflammatory and antipyretic properties Gebert et at., US. Patent 3,915,980, disclose such compounds wherein Al can be phenol or pen (Clue) alkyd, as intermediates to imidazolyl-2-thioalkanoic acid esters.
Iverson, Act Chum. Stand. 21, 279 (1967) reports a compound having the formula:

I

I N

wherein R can be -C02H or -CHINOOK, but does not report a pharmaceutical use for the compound.
SUMMARY OF THE INVENTION
The invention resides in the discovery that DBH
can be inhibited by a compound having an imidazole-2-carboxylic acid or 2~aminomethyl imidazole moiety and a phenethylamine analog moiety. More particularly, the invention is selected novel compounds having the formula:
R

SHEA N N
lo \=~/
X
wherein Y is -H, -OH, -OUCH, -F, -CF3 or Clue alkyd;

X is -H, -OH, -OUCH, -F, -CF3, Clue y or any accessible combination thereof up to four substituents;
R is -KIWI or -CEI2NHRl;
Al is -H, phenol or bouncily; and, n is 0-4, or a pharmaceutically acceptable acid addition salt or hydrate thereof, provided that when R is -KIWI or 35 -CHINOOK, X is -H and n is 1, Y it not -H.

1 In one preferred embodiment of the compounds of the invention, R is -KIWI and n is 1 or 3. In a second such preferred embodiment, R is -CH2NHRl; it -H or -OH Al is -H or bouncily; and n is 1.
The invention is also a method of inhibiting DBH
activity in mammals which comprises administering internally to a subject an effective amount of a compound having the formula:

SHEA N
Ye ' I' X

wherein Y is -H, -OH, -OUCH, -F, -CF3, Clue - alkyd;
X is -H., -OH, -OUCH, -F, -CF3, Clue alkyd, or any accessible combination thereof up to four substituents;
R is -KIWI or -CH2NHRl;
Al is -H, phenol or bouncily; and, n is 0-4, or a pharmaceutically acceptable acid addition salt or hydrate thereof.
In the preferred method of the invention, R is -KIWI and n is 1 or 3, or, R is -CH2NHRl, Y is -H or -OH, R is -H or bouncily, and n is 1.
The invention includes pharmaceutical compositions comprising the compounds which are useful in the method of the invention and a pharmaceutical carrier.
Pharmaceutically acceptable acid addition salts, and hydrates, are included within the above formulae.

to 1 The invention is also a compound having the formulas COO
on yl~xl W

lo wherein ye is -H, -OUCH, -F, -CF3 or Clue alkyd;
Al is H, -OUCH, -F, -CF3 or Clue 15 alkyd, or any accessible combination thereof up to four substitutents.
Al is -I, phenol or bouncily; and, n is 0-4.
This compound is converted to the 2~aminomethyl imidazole 20 of the invention by reducing the compound.
the invention is also a compound having the formula:
M

2 nun Y Al ' wherein I is -H, -OUCH, -F, -CF3 or Clue alkyd;
Al is -H, -OUCH, -F, -CF3 or Clue or any accessible combination thereon up to four 35 substituents;

35~

1 n is 0-4; and, M is an organic salt of an alkali metal.
This compound is converted to the imidazole-2-carboxylic acid of the invention by quenching with COY.
DETAILED DESCRIPTION OF THE INVENTION
_ _ _ _ .
The compounds of the invention contain a weak metal-chelating functional group. They also contain a phenol moiety as do phene~hylamine analog inhibitors such as benzyloxyamine, benzylhydrazine~ tryptamine and 10serotonin.
The compounds of the invention can be prepared from corresponding 2-mercapto-1-(4-methoxyaryl)imidazoles by procedures such as those illustrated in the Examples below. Starting mercaptoimidazoles are known (see, for 15 example, US. 3,915,980 and US 1,155,580) or can be prepared from corresponding benzaldehydes, which are known and described in published references or are readily accessible by known techniques, such as illustrated in Scheme I, depicted below, wherein Al and ye are X and 20 Y, respectively, except that when Y is -OH, ye is -OUCH and when X is -OH, Al is -OUCH. As illustrated, n is one, although n can be 0-4. Scheme I
illustrates reductive lamination of the benæaldehydes (I) with an amnoacetaldehyde acutely followed by reduction by, 25 for example, catalytic hydrogenation or treatment with a reducing agent such as Nub, Lyle or Allah, to provide intermediate substituted benzylamines (It). Upon reaction with acidic thiocyanate, the intermediates II
yield starting mercaptoimidazole compounds 5III) which can 30 be converted to the compounds of the invention by procedures known in the art, such as described below and as illustrated in the examples which hollow.

1 Scheme I

OH OH CH(0CH OH ) NC~2CH(0GH2c~3)2 I Y X

NH~H~CH(0CH2CH3)2 or Nub Y x1 II
. SO
HJKSCN Jo N n ye . IT .
The l-phenyl substituted 2-mercaptoimidazole starting compounds (n it O) are preferably prepared by 20 reaction of an appropriately substituted phenol isothiocyanate with an aminoacetaldehyde acutely followed by strong acid catalyzed cyclization, as illustrated in Example 1, below.
The compounds wherein n is 2,3 or 4 are 25 preferably prepared as described in Example 4, below.
Coupling of substituted phenol alkanoic acids as the acid chlorides with aminoacetaldehyde acetals and subsequent reduction provides such intermediate substituted phenol alkylamines.
ye in Scheme I is the same as Y except that when Y is -OH, ye is -OUCH; deprotection of the 4-alkoxy group with, for example, Brie or Her, or nucleophilic aromatic substitution with dilute hydroxide, provides the phenol (Y is -OH). X may be one or more 35 substituents at the I-, 3-, 5- or 6-positions provided the combination of substituents is accessible, that is, does not result in significant instability due to steno so 1 hindrance When Al is OKAY, it can be deprotected as described above for Y .
Rune nickel desulfurization of the starting mercaptoimidazoles (III) provides parent aralkylimidazoles 5 which can be treated with an organic salt of an alkali metal to provide intermediate aralkyl substituted 2-alkaliimidazoles The alkali substituent can be replaced such as by quenching with disubstituted formamides to give the 2-aldehydes, as in Example 5, or with COY to give the 2-carboxylic acid, as in Example 9.
The corresponding substituted amino methyl compounds OR is -C~2NHRl wherein Al is -I t phenol or bouncily) can be prepared from the 2-aldehydes by reduction of intermediate 2-aldoximes or o-alkyl ethers of 152-aldoximes as illustrated in Example 6, or by reductive lamination with primary or secondary amine as illustrated in Example 7.
The pharmaceutically acceptable acid addition salts of the compounds of the invention are formed with strung or moderately strong organic or inorganic acids by methods known to the art. For example, the base is reacted with an inorganic or organic acid in an aqueous miscible solvent such as ethanol with isolation of the salt by removing the solvent or in an aqueous immiscible 25 solvent when the acid is soluble therein, such as ethyl ether or chloroform, with the described salt separating directly or isolated by removing the solvent. Exemplary of the salts which are included in this invention are Malta, fumarate, lactate, oxalate, methanesulfonate, 30 ethanesulfonate, benzensulfonate, tart rate, citrate, hydrochloride, hydrobromide, sulfate, phosphate and nitrate salts.
The compounds of the invention, because they can be used to inhibit DUB activity, have therapeutic value as 35 diuretic, natriuretic, cardiotonic, anti hypertensive and -35~
g 1 vasodilator agents, as well as antiulcerogenic and anti Parkinson disease agents. Compounds of the invention and the compounds wherein R is KIWI or CHINOOK, Y is -H, X is -H and n is 1, which compounds are useful in the method of the invention, were screened for in vitro DBH inhibition by a standard procedure for assaying conversion of tyramine to octopamine in the presence of BY Octopamine was assayed following sodium peridot oxidation to p-hydroxy-10 benzaldehyde by measuring spectrophotometric absorbency await no. Results are given in Table I, below. Inhibition is given in molar concentration of compound at which DBH
activity was halved (ISSUE). Melting points (my) are given in C. Fusaric acid, by this test was found to 15 have an ISSUE of 8x10 Table I
EYE my IT
R Y X n C~2NH2-2H3r ox H 1 252-254 3~5 x 10 5 KIWI- act Dick) 1.1 x 10 5 KIWI Hal OH H 1 Dick) 9.0 x 10 5 KIWI HO ox H 3 Dick) 7.0 x 10 5 Kiwi Hal ooze H 1 Dick) 7.5 x 10 5 CH2NHC6~s Brie I 1 198-200 ' 10 4 KIWI Hal OUCH H 3 Dick) OOZE x 10 5 SHEEHAN clue H 1 185-187 2.4 x 10 4 CR2NHc6~s-2Hcl H 1 ~06 1.0 x 10 4 The following procedure was used to test, for in viva activity, compounds which can be used to inhibit DO
activity in mammals, including certain illustrative compounds of the invention. 'rho compounds wherein R is -KIWI or -CHINOOK, X is -H, Y is -H and n is 1 35 are not compounds of the invention but can be used in the to 1 method of the invention.
Male, Okamoto-Aoki strain spontaneously hypertensive rats, aged 16-20 weeks, were used for testing. The afternoon before testing the animals were fasted and the following morning the first dose of the test compound was administered, pro., along with a 25 ml/kg load of normal saline. The animals were then placed in metabolism cages, three per cage, and urine was collected for three hours and subsequently analyzed for sodium, potassium, and creatinine. Indirect systolic blood pressure and heart rate were measured via a tail-cuff method and the animals received an identical second dose of the test compound. Two hours after the second dose, the systolic blood pressure and heart rate 15 were again determined. Drugs were administered as a solution or suspension in normal saline with 0.02%
ascorbic acid Three rats weighing 270-370 g were used. Each received two intraperitoneal injections, in a 24 hour 20 period, of a dose volume of 5 my and a dose concentration of 50 mg/kg or 25 mg/kg, in 0.3% Nail, following a 24 hour pretreatment dose. Averaged results were as tabulated in Table II, below. Averaged results with control animals, three per experiment, are reported in parentheses below 25 results of test animals.

cay O O O O O O O O
o 0 0 I I 0 'J co u eel I: 3 I 8 aye S., 0 a us o 0 I C It 0 10 ,, Al O

O o z kiwi owe 2 0 . c -- " 0 ED
Jo .

. Cal . I,. .
Jo Jo Us o o C:

Jo U
Jo _ o Y' $ '`
a) +
_, Jo ox Jo ,,., _ = = C, , I U U

O 0 11 D: 11 I O I S O CJ O Jo c,7 o 11 11 1'_, 11 00 I 11 11 11 0 11 11 11 11 0 11 11 11 11 I X X D X X e 1 Analysis of the above-tabulated results indicate that the compounds inhibit BY activity as shown by the ISSUE data and/or by their in viva natriuretic, diuretic, and antihyper~ensive and/or cardiotonic activity. For 5 example, the compound in which R is -KIWI, X and Y are -H and n is 3 showed significant in Volvo activity as a natriuretic, diuretic, anti hypertensive and cardiotonic agent; the compound in which R is -KIWI, Y is -OH, X is -H, and n is 3 showed significant diuretic activity; the 10 compound in which R is -SHEEHAN, Y is -Out X is Ho and n is 1 showed significant anti hypertensive activity; the compound in which R is -CHINOOK, Y is -OH X is -H
and n is 1 showed significant cardiotonic activity Compounds having diuretic activity are known to be useful 15 as antihypertensives.
The compounds can be incorporated into convenient dosage unit forms such as capsules, tablets or injectable preparations. Pharmaceutical carriers which can be employed can be solid or liquid. Solid carriers include, 20 among others, lactose, terra alga, sucrose, talc, gelatin, ajar, pectin Acadia, magnesium stout, and Starkey acid. Liquid carriers include, among others, syrup, peanut oil, olive oil and water. Similarly, the carrier or delineate may include any time delay material, such as glycerol menstruate or glycerol distrait, alone or with a wax. The amount of solid carrier will vary widely but, preferably, will be from about 25 my to about 1 g per dosage unit. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin 30 capsule, sterile injectable liquid such as an ampule, or an aqueous or non aqueous liquid suspension.
The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving mixing, granulating and compressing, Winnie necessary, for tablet forms, or mixing, filling and dissolving the ingredients as appropriate to give the desired oral or parenteral end products.
Doses of the present compounds in a pharmaceutical dosage unit will be an effective amount, that is, a nontoxic quantity selected from the range of 0.1-1,000 mg/kg of active compound, preferably 10-100 mg/kg. The selected dose is administered to a patient in need of treatment from 1-5 times daily, orally rectally by injection or by infusion. Parenteral administration, 10 which uses a Ion dose is preferred. However, oral administration, at a higher dose, can also be used when safe and convenient for the patient.
The following examples are illustrative of preparation of compounds of the invention (Examples 6-14) 15 or intermediates therefore (Examples 1-5). The starting compounds of Examples 1-4 are commercially available or are prepared by known techniques. The examples are not intended to limit the scope of the invention as defined hereinabove and as claimed below. All temperatures and 20 melting points (my) are degrees Celsius (C).

SO
I

3 0 H3CO

A solution of 10 g t.06 mole) of p-methoxyphenyl-35 isothiocyanate in 100 ml of SCHICK was treated with 6.3 g 1 (.06 mole) of aminoacetaldehyde dimeth~l acutely The solvent was evaporated and the residue was recrystallized from ethanol to yield N-Ip-methoxyphenyl)-N' (~,B-dimethoxyethyl)thiourea, 902 g (57~). A suspension of this Thor in a solution of 5 ml of concentrated H2SO4 and 20 ml of HO was reflexed for 3 hr. The mixture was cooled and a solid was filtered, washed with HO and dried. Recrystallization from ethanol gave 1-(4-methoxyphenyl)-2-mercaptomidazole, 4.9 g (70%), my 10 215-?
The compound is deprotected as illustrated, for example, in Example 6, below, to prepare the phenol (Y is -OH).

SO
SHEEHAN N

A mixture of 13.6 g (0.1 mole) of anisaldehyde, 13.3 9 (0.1 mole) of aminoacetaldehyde deathly acutely and 1 ml of SHEA was heated at 95 for 10 minutes. A
residue was dissolved in 150 ml of ethanol and hydrogenated over 10% Pod on carbon at 50 psi t0-34 Ma) until Ho uptake was complete The catalyst was filtered and the filtrate was treated with 10.4 g-(0.107 mole) of KSCN, 40 ml of ON Hal and 40 ml of HO. The mixture was reflexed, letting the solvent evaporate until the volume of the reaction mixture was 100 ml. After 45 minutes, the mixture was cooled, and a solid was filtered, washed with 35 HO and dried. Recrystallization from ethanol gave to , lo 1 tl-(4-metho~ybenzyl)-2-mercaptomidazole, 15.0 g (68%), my I -142 .

SO
By 2 \ N

A solution of Lowe g (705 mole) of Brigham-metho~ybenzaldehyde and 6.65 g (.05 mole) of amino-acetaldehyde deathly acutely in 25 ml of ethanol was reflexed for 30 minutes. The solvent was evaporated and the residue was dissolved in SCHICK. The SCHICK
20 solution of the Showoff base was washed with saturated aqueous Nail, dried ~K2C03)and filtered, and the solvent was evaporated Residual Showoff base was dissolved in 100 ml of methanol, cooled to So, and treated with 5.0 g of Nub. The reaction mixture was 25 allowed to warm to 22 and, after 4 ho, the solvent was evaporated. The residue was taken up in deathly ether washed with Ho dried (McCoy) and filtered, and the solvent was evaporated. A solution of the residue in SCHICK, upon treatment with ethereal Hal gave, on 30 standing, crystals of N-(3-bromo-4-methoxybenzyl) aminoacetaldehyde diethylacetal hydrochloride, 10.75 g (58~), my. 112-120.
A solution of 10.74 g (.029 mole) of N-(3-bromo-4-methoxybenzyl)aminoacetaldehyde deathly 35 acutely hydrochloride and 3.37 g (0.35 mole) of KSCN in 50 1 ml of H20, 50 ml of ethanol and 5 ml of ON Hal was eefluxed for 4.5 hr. One hundred ml of H20 was added and the mixture was cooled. A solid was filtered, washed with H20 and dried. Recrystallization from ethanol gave 1-~3-bromo-4-methoxybenzyl)-2-mercaptoimidazole, 603 9 (72%), my 188.

SHEA H2~3~

A solution of 12.5 g (.07 mole) of p-methoxyphenylpropionic acid in 100 ml of SCHICK and one drop of pardon was treated with 9.8 g Tao mole of oxalyl chloride. After 2.5 ho, the solvents were thoroughly evaporated to give the acid chloride as an oil. A solution of the acid chloride in 100 ml of SCHICK was slowly added to a cold (0) solution of 14.7 g (0.14 mole) of aminoacetaldehyde dim ethyl acutely in 300 ml of SCHICK at a rate such that the temperature stayed below 20. After 1 ho, the reaction mixture was poured into H20, and the SCHICK layer was separated and washed with aqueous Nikko, 0.5N Hal and H20.
Following drying and evaporation of the solvent, No -dimethoxyethyl)-p-methoxyphenylproponamide was left as a solid, 10.3 g (55%)~ A solution of this aside in 300 ml of deathly ether was slowly added to a slurry of 4.0 g of Lyle in 400 ml of deathly ether and 350 ml of tetrahydrofuran THIEF). After 3.5 ho at 22, excess Lyle was cautiously destroyed, the reaction mixture was filtered and the filtrate was evaporated. The residue was dissolved in 100 ml of 0.15N Hal, washed with deathly 1 ether, gasified with Nikko and extracted with deathly ether. The extracts were dried (MgSO4)and the solvents evaporated to give N-[3-(4-methoxyphenyl)-propyl]-amino-acetaldehyde dim ethyl acutely, 4.6 g (52%), as an unstable oil.
A solution of 3.62 g (.014 mole) of N-[3~(4-methoxyphenyl)propyl]dimethyl acutely and 1.4 g (.0144 mole) of KSCN in 20 ml of ethanol, 5 ml of Ha and 2 ml of concentrated Hal was reflexed for five ho Fifty ml of 10 HO was added, the mixture was cooled and a solid was filtered, washed with HO and dried. Recrystallization from ethanol gave 1-[3-(4-methoxyphenyl) propel-mercaptoimidazole~ 2.4 9 (69%), my 108-109.
Example 5 SHEA

OH

A mixture of 15.0 9 (0.068 mole) of 1-(4-methoxy-benzyl)~2-mercaptoimidazole and 80 g of Renoir nickel in 800 ml of ethanol was reflexed for 4 hr. The nickel was 30 filtered off and the filtrate was evaporated. The residue was dissolved in 100 ml of lo Hal and this solution was washed with deathly ether. The aqueous layer was gasified with Nikko and extracted with ethyl acetate. The extracts were dried (K2CO3), filtered and the solvent 35 was evaporated, to give 1- (4-methoxybenzyl)imidazole as to 1 an oil, 8.7 g (68~). A solution of this oil in acetone was treated with hexamic acid and deathly ether, and the hexamate salt was crystallized, my 157-159.
A solution of 4.9 g t.026 mole) of 1 (4-methoxy-benzyl)lmidazole in a mixture of 150 ml of deathly ether and 30 ml of tetrahydrofuran THIEF) under an atmosphere of argon was cooled to 60 and treated with 18 ml of a 107M solution of n-butyl lithium in hexane. After 1.5 ho, 2.25 g ( owe mole) of dimethylformamide (DMF) was added, 10 and the reaction mixture was warmed to 22. After 30 mint the reaction mixture way treated with lo ml of 1.5 Hal, and this aqueous mixture was washed with deathly ether. The acidic layer was gasified with Nikko and extracted with deathly ether. Toe extracts were washed 15 well with HO, dried (K2CO3), and filtered and the solvent way evaporated. Thy residue was a pale yellow unstable oil, l-(4-methoxybenzyl) 2-formylimidazole, 4.9 g (87%).
Example 6 r NH2 SHEA N N

Ho 2HBr A vigorously stirred suspension of 2.5 9 (.012 mole) of l-(4-methoxybenzyl)-2-formyl imidazole in 30 ml 30 of HO was treated with 6 g of Chicano OWE and 1.5 g of NOAH Hal. After 2 ho, the l-(4-methoxybenzyl~-formula imidazole oxide had solidified. The oxide was filtered, washed with HO, dried and recrystallized from ethanol to give lo g (68%), my 201-204.
A solution of the oxide in 100 ml of ethanol was l hydrogenated over Ryan nickel at spa psi (0.34 Ma) for 3 hr. The catalyst was filtered, the filtrate was treated with ethereal Hal and the solvent was evaporated. The residue was recrystallized from ethanol three times to give 1-(4-methoxybenzyl)-2-aminomethyl imidazole dodder-chloride, 0.53 g (22~). A suspension of this salt in 50 ml of Shekel was washed with aqueous Nikko. The C~2Cl2 solution of the free base was dried (K2CO3) and filtered. The filtrate was treated with a solution of lo lo g (~004 mole of Brie in 2.5 ml of Shekel.
After 6 ho, methanol was cautiously added and all the solvents were evaporated. The residue was recrystallized from a mixture of methanol and deathly ether to give l-(4-hydroxybenzyl)-2-aminomethyl imidazole dodder-15 bromide, 0.17 g (27%), my 252-254.
Example 7 r NHC6H5 2 N clue Jo Jo A solution of 1.88 g (.0087 mole) of l-(4-methoxy-bouncily) formula imidazole and 0.81 g (.0087 mole) of aniline in 20 ml of ethanol was reflexed for lo hr. The 30 reaction mixture was cooled to 22 and treated with 3.0 g of Nub. After 3 ho, the solvent was evaporated.
The residue was taken up in deathly ether, washed with HO, dried and filtered and the solvent was evaporated.
The residue was converted to its dihydrochloride salt in a 35 mixture of SCHICK and ethyl acetate with ethereal Hal, I

l to give 1-~4-methoxybenæyl)~2-phenylaminomethyl imidazole dihydrochloride, 1.8 g (56%), my 146-157.
Example 8 r NHCHfj~!5 Ho SHEA No Y Brie A suspension of 1.6 g (.0044 mole) ox 15 1-(4-methoxybenzyl)-2-phenylaminomethyl imidazole dihydrochloride in 100 ml of SCHICK was converted to its free base by washing with aqueous Nikko. The Shekel was dried (K2CO3)~ and filtered, and the filtrate was treated with a solution of 3.3 9 (.013 mole) 20 of Brie in 9 ml of Shekel. After 3 ho, methanol was cautiously added and all the solvents wets evaporated.
The residue was recrystallized from methanol and deathly ether to give l-(4-hydroxybenzyl)-2-phenylaminomethyl imidazole dihydrobromide, 0.73 gym (39%), my 198-20n.
Example 9 KIWI

1 A mixture ox 5.0 g (~02 mole) of 1-[3-(4-methoxy~
phenyl)propyl]-2-mercaptoimidazole, 40 g of Ryan nickel and 200 ml of ethanol was reflexed for 4 hr. The My was filtered off and the filtrate was evaporated.
residue was dissolved in 25 ml of lo Hal, and washed with deathly other. The aqueous phase was buzzed with aqueous Nikko and extracted with Doyle ether. The extracts were dried over K2CO3 and filtered, and the solvent was evaporated. l-[3-(4-methoxyphenyl) 10 propyl]imidazole remained as an oil, 2.5 g (58%). This oil was dissolved in 100 ml of deathly ether and cooled to -60 under an argon atmosphere. A lo EM solution of n-butyl lithium in hexane, 8.2 ml, was added, and the solution was stirred for 1.5 hr. The argon was replaced 15 with bone dry COY, and the reaction was stirred vigorously until COY uptake ceased. The reaction mixture was warmed to 22, and the white lithium salt was filtered. The filter cake was washed with deathly ether, and dissolved in 10 ml of HO Hal, lo, was 20 added to phi, at which pi a product crystallized. The product was filtered, washed with HO, and dried. The product was converted to its Hal salt by treatment of an ethanolic solution of the above filtered material with ethereal Hal and deathly ether. The resultant 1-[3-(4-25 methoxyphenyl)propyl]imidazole-2-carboxylic acid hydrochloride was 1.2 g (35~), my 130 (doe).
Example 10 N -I N

H CO clue I ' 'lt'"~9 I

1 Substantially by the procedure of Example 9, except that the starting mercaptoimidazole was 1 (4-methoxybenzyl)mercaptoimidazole~ the compound 1-(4-methoxybenzyl)imidazole-2-carboxylic acid hydrochloride mop 115 (doe), was prepared.
Example 11 I ON N
HUT O Ho A suspension of 1.1 9 ~.0037 mole) of 3-(4-methoxyphenyljpropyl]imidazole-2-carboxylic acid hydrochloride in 100 ml of C~2C12 at 5 was treated . with a solution of 2.8 g (.011 mole) of Brie in 7 ml of SCHICK. The mixture was allowed to warm to 22, and stirred for 5 hr. Methanol was cautiously added, and when a vigorous reaction was over, all solvents were evaporated. A residue was dissolved in 10 ml of HO and the pi was adjusted to 3.5 with aqueous Nikko. The product crystallized, was filtered, washed with HO and dried. Recrystallization from methanol gave 1 [3-(4-hydroxyphenyl) propel imidazole-2-carboxylic acid, hemihydrate, 0.65 g (71%), my 136 (doe).
Example 12 ~\,~ SHEA Jo so 1 substantially by the procedure of Example 9, except that the starting mercaptoimidazole was 1-(4-methoxybenzyl) mercaptoimidazole, the compound 1-(4-methoxybenzyl)imidazole-2-carboxylic acid, hydra-chloride, my 115, was prepared. Substantially following the procedure of Example 11, the carboxylic acid was converted to l-(4-me~hoxybenzyl)imidazole-2-carboxylic acid hydrochloride hydrate, mop. 135-142 (doe).
Example 13 C~2N~2 I/ N N clue Substantially by the procedure of Example S, except that the starting mercaptoimidazole was l-benzyl-2-mercaptoimidazole, a commercially available compound, the compound, 1-benzyl-2-formyl imidazole, was prepared.
Substantially following the procedure of Example 6, the bouncily imidazole was converted to l-benzyl-2-aminomethyl imidazole dihydrochloride, my 185-187.
Example r~C6H5 l N N
. I

Substantially by the procedure of Example 5, except that the starting mercaptoimidazole was bouncily-~2~35~
I

1 mercaptoimida~ole, a commercially available compound, the compound, l-benzyl-2-formyi imidazole, was prepared.
Substantially following the procedure of Example 7, the bouncily imidazole was converted to l-benzyl-2-benzyl aminome~hyl imidazole dihydrochloride, mop 206.
kite the preferred embodiments of the invention are illustrated by the above, it is to be understood that the invention is not limited to the precise constructions herein disclosed and what the right to all modifications coming within the scope of the following claims is reserved.

I

Claims

Claims:

1. A process for preparing compounds of the following structure (I) (I) wherein:
Y is -H, -OH, -OCH3, -F, -CF3, or C1-4 alkyl;
X is -H, -OH, -OCH3, -F, CF3, or C1-4 alkyl, or any accessible combination thereof up to four substituents;
R is -CH2NHR1 or -CO2H;
R1 is -H, phenyl or benzyl; and, n is 0-4, or a pharmaceutically acceptable acid addition salt or hydrate thereof, provided that when R is -CO2H or -CH2NHC6H5, X
is -H and when n is 1, Y is not -H, from compounds of the following structure (II):

(II) wherein:
y1 is -H, -OCH3, -F, -CF3, or C1-4 alkyl;

x1 is -H, -OCH3, -F, -CF3, or C1-4 alkyl;
or any accessible combination thereof of up to four substituents; and n is 0-4, which comprises reduction of intermediate 2-aldoximes or 0-alkyl ethers of 2-aldoximes formed from structure (II) compounds or reductive amination of structure (II) compounds, and, when X1 and/or y1 are -OCH3, optionally deprotecting the methoxy group to prepare a structure (I) compound where X and/or Y are -OH.

2. A process for the preparation of 1-(4-methoxybenzyl, -2-aminomethyl imidazole which comprises reduction of 1-(4-methoxybenzyl)-2-formyl imidazole oxime.

3. A process for the preparation of 1-(4-hydroxy-benzyl)-2-aminomethyl imidazole which comprises deprotection of 1-(4-methoxybenzyl)-2-aminomethyl imidazole.

4. A process for the preparation of 1-(4-methoxybenzyl -2-phenylaminomethyl imidazole which comprises reductive amination of 1-(4-methoxybenzyl)-2-formyl imidazole.

5. A process for the preparation of 1-(4-hydroxybenzyl) -2-phenylaminomethyl imidazole which comprises deprotection of 1-(4-methoxybenzyl)-2-phenylaminomethyl imidazole.

6. A process for the preparation of 1-benzyl-2-aminomethyl imidazole which comprises reduction of 1-benzyl--2-formyl imidazole oxime.

7. A process for the preparation of 1-benzyl-2 benzylaminomethyl imidazole which comprises reductive amination of 1-benzyl-2-formyl imidazole.

8. A compound having the formula:

wherein:
Y is -H, -OH, -OCH3, -F, -CF3 or C1-4 alkyl;
X is -H, -OH, -OCH3, -F, -CF3 or C1-4 alkyl, or any accessible combination thereof up to four substituents;
R is -CO2H or -CH2NHR1;
R1 is -H, phenyl or benzyl; and, n is 0-4, or a pharmaceutically-acceptable acid addition salt or hydrate thereof, provided that when R is -CO2H or -CH2NHC6H5, X is -H and n is 1, Y is not -H whenever prepared by the process of Claim 1 or an obvious chemical equivalent thereof.

9. 1-(4-methoxybenzyl)-2-aminomethyl imidazole whenever prepared by the process of Claim 2 or an obvious chemical equivalent thereof.

10. 1-(4-hydroxybenzyl)-2-aminomethyl imidazole whenever prepared by the process of Claim 3 or an obvious chemical equivalent thereof.

11. 1-(4-methoxybenzyl)-2-phenylaminomethyl imidazole whenever prepared by the process of Claim 4 or an obvious chemical equivalent thereof.

12. 1-(4-hydroxybenzyl)-2 phenylaminomethyl imidazole whenever prepared by the process of Claim 5 or an obvious chemical equivalent thereof.

13. 1-benzyl-2-aminomethyl imidazole whenever prepared by the process of Claim 6 or an obvious chemical equivalent thereof.

14. 1-benzyl-2-benzylaminomethyl imidazole whenever prepared by the process of Claim 7 or an obvious chemical equivalent thereof.